The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index; 15 of the 21 sources its claims cite were checked for support.
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings
Open accessAbstract
Obesity is a major public health crisis. Multi-specific peptides have emerged as promising therapeutic strategies for clinical weight loss. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are endogenous incretins that regulate weight through their receptors (R). AMG 133 (maridebart cafraglutide) is a bispecific molecule engineered by conjugating a fully human monoclonal anti-human GIPR antagonist antibody to two GLP-1 analogue agonist peptides using amino acid linkers. Here, we confirm the GIPR antagonist and GLP-1R agonist activities in cell-based systems and report the ability of AMG 133 to reduce body weight and improve metabolic markers in male obese mice and cynomolgus monkeys. In a phase 1, randomized, double-blind, placebo-controlled clinical study in participants with obesity ( NCT04478708 ), AMG 133 had an acceptable safety and tolerability profile along with pronounced dose-dependent weight loss. In the multiple ascending dose cohorts, weight loss was maintained for up to 150 days after the last dose. These findings support continued clinical evaluation of AMG 133.
Overview
CoChat Summary
TL;DR
AMG 133 (maridebart cafraglutide), a bispecific GLP-1R agonist/GIPR antagonist, reduced body weight and improved metabolic markers in preclinical models and showed dose-dependent weight loss with acceptable safety in a phase 1 obesity study. In the multiple ascending dose (MAD) cohorts, weight loss persisted up to 150 days after the last dose.
Key findings
- In cell-based assays, AMG 133 antagonized native GIP at human GIPR with an IC50 of 42.4 nM and at cynomolgus monkey GIPR with an IC50 of 26.5 nM; it also agonized human GLP-1R with an EC50 of 24.4 pM.
- In male obese mice, the AMG 133 murine surrogate reduced body weight, food intake, blood glucose, plasma insulin, and lipid levels; in one db/db mouse study, maximal body-weight loss occurred within 24 h and remained significant up to 216 h after injection.
- In obese cynomolgus monkeys, weekly s.c. dosing for 6 weeks reduced body weight by 11% at 0.25 mg kg−1 and 13% at 0.75 mg kg−1, with reductions in total energy intake, fasting triglycerides, fasting insulin, total cholesterol, and LDL-C.
- In the phase 1 study, 49 participants were enrolled into SAD cohorts and 26 into MAD cohorts; in MAD, the 420 mg Q4W group had a mean body-weight change of −14.5% by day 85, and weight loss in that group remained up to −11.2% at 150 days after the last dose.
Methods
- Preclinical program: in vitro receptor assays plus PK/pharmacology studies in male mice (including db/db and DIO models) and obese cynomolgus monkeys; analyses included body weight, food intake, glucose, insulin, and lipid measurements.
- Phase 1 program: first-in-human, double-blind, randomized, placebo-controlled study (NCT04478708) with SAD and MAD cohorts in adults with obesity; 75 participants were in the final reported SAD/MAD dataset.
- Main analyses were descriptive for the clinical study (PK/PD/safety), with PK estimated by noncompartmental analysis; animal studies used ANOVA/mixed-effects methods with multiple-comparison testing.
Limitations
- The paper states the main limitation of the first-in-human study was the small sample size, requiring cautious interpretation of PD effects and metabolic parameters.
- The participants had neither diabetes nor high triglyceride/cholesterol levels, which the paper says limits generalizability of metabolic findings.
- The study had no active comparator arm, and the human trial design could not separate the individual contributions of GIPR antagonism versus GLP-1 agonism to weight loss.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 AMG 133 exhibited GIPR antagonist and GLP-1R agonist activities in vitro and extended PK profiles. a, Structure of AMG 133. The GLP-1 analogue peptide sequence is H[Aib]EGTFTSDYSSYLEEQAAKEFIAWLVKGGG(GGGGS)3 K(BrAc){CONH2}. b, In vitro potency of AMG 133. c–e, PK properties after a single dose of 5 mg kg−1 i.v. administration of AMG 133 to CD-1 mice (c), a single dose of 3 mg kg−1 s.c. administration of AMG 133 to female cynomolgus monkeys (d) and s.c. administration of AMG 133 to obese male cynomolgus monkeys (e). AUC, area under the curve; AUCinf, AUC zero to infinity; Vss, volume in steady state; CL, clearance; F, fraction absorbed; EC50, half maximal effective concentration; GIPR, glucose-dependent insulinotropic polypeptide receptor; GLP-1R, glucagon-like peptide-1 receptor; IC50, half maximal inhibitory concentration; IV, intravenous; PK, pharmacokinetic; SC, subcutaneous; tmax, time of maximum observed concentration.](https://figures.cochat.ai/paper-figures/1aef7a56c7684ef888e175df6f70e48a/a-gipr-antagonist-conjugated-to-glp-1-analogues-promotes-weight-loss-with-figure-1.jpg)










Verification
Claims the paper makes
9 Valid · 1 Not valid · 3 Not checked · 136 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical species and humans, mAbs are known to have minimal brain penetration, at around 0.1–0.4% of mAb plasma concentration35,36.”
§ A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings > Discussion
What the sources say
- Partly supportedcites [35] Garg, A. & Balthasar, J. P. Investigation of the influence of FcRn on the distribution of IgG to the brain. AAPS J. 11, 553–557 (2009). sourceExperimental — accuracy not yet measured
Our copy supports the magnitude only for one preclinical species: the RESULTS report that control mice 'showed little distribution of IgG to the brain, as indicated by the low brain/plasma AUC ratio (0.0022±0.00015)' — i.e. ~0.22%, within the cited 0.1–0.4% window — and the DISCUSSION states plasma cumulative exposure was 'approximately 500-fold greater' than brain exposure for the mAb 7E3. However, the study is a mouse experiment with a single IgG1 antibody, and the ratio is a brain/plasma AUC (exposure) ratio rather than a steady-state brain-to-plasma concentration ratio. Nothing in our copy addresses humans: searched for human brain penetration/CNS levels of mAbs, percent-of-plasma figures in humans, and CSF/human data — the only human material is in references (e.g. placental FcRn, Schlachetzki/Pardridge BBB FcRn expression). So the 'in preclinical species and humans' extension and the general 0.1–0.4% range across mAbs are not supported by this source. (LLM, conf=0.75)
- Supportedcites [36] Shah, D. K. & Betts, A. M. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs 5, 297–305 (2013). source
The Abstract and Table 1 (Discussion) of Shah & Betts (2013) give the brain antibody biodistribution coefficient as 0.351% of plasma concentration, the lowest of all tissues (~0.3% in the Discussion text), and the Discussion states this value is comparable to literature plasma-to-brain ratios as high as ~500 (0.2%). The paper's hypothesis and validation explicitly cover mouse, rat, monkey and human (Abstract; Results/Discussion on the rat and monkey+human validation data sets), so the cross-species 'minimal brain penetration at roughly 0.1-0.4% of plasma' paraphrase is carried by our copy; the only element not literally stated is the 0.1% lower bound, but the cited range brackets the paper's 0.2-0.351% values. (LLM, conf=0.85)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The safety profile of AMG 133 was similar to that of GLP-1RAs, including unimolecular GLP-1/GIPR agonist peptides6,7.”
§ A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings > Discussion
What the sources say
- Partly supportedcites [6] Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 (2021). sourceExperimental — accuracy not yet measured
The Safety and Side-Effect Profile section reports adverse events for semaglutide, a GLP-1 receptor agonist, and the discussion (p. 1000) describes its safety findings as consistent with the GLP-1 receptor agonist class. The paper does not assess AMG 133 or unimolecular GLP-1/GIPR agonist peptides, so it cannot establish the claimed similarity for those treatments. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [7] Jastreboff, A. M., Aronne, L. J. & Stefanski, A. Tirzepatide once weekly for the treatment of obesity. Reply. N. Engl. J. Med. 387, 1434–1435 (2022). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“and genetic preclinical models30,31,39,40 support the role of GIPR antagonism as a method to promote weight loss and prevent weight gain.”
§ A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings > Discussion
What the sources say
- Partly supportedcites [30] Althage, M. C. et al. Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J. Biol. Chem. 283, 18365–18376 (2008). sourceExperimental — accuracy not yet measured
Althage et al. (2008) is a genetic preclinical model that supports reduced GIP signalling limiting diet-induced weight gain: the DISCUSSION states 'as in GIPR-/- mice, animals genetically engineered to lack GIP-producing cells also resist development of high fat diet-induced obesity and insulin resistance,' and the Abstract concludes 'total inhibition of GIPR signaling reduces high fat diet-induced obesity and insulin resistance.' However, GIPR antagonism itself is named only as a hypothetical option ('Two potential strategies... would be to 1) inhibit GIPR activity by administration of GIPR antagonists and 2) inhibit GIP production, release, and/or action'); no antagonist was administered in this work, whose own manipulation ablates K cells (ligand loss) rather than blocking the receptor. Nor does the paper show promotion of weight loss: its data are attenuated weight gain on a high fat diet for 35 weeks (55% vs 11% over chow) with no reversal of established obesity, so the 'promote weight loss' and pharmacological-antagonism parts of the claim are not supported by this source. (LLM, conf=0.75)
- Not checked — no full text of the sourcecites [31] Miyawaki, K. et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8, 738–742 (2002). source
- Partly supportedcites [39] Akbari, P. et al. Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity. Science https://doi.org/10.1126/science.abf8683 (2021). sourceExperimental — accuracy not yet measured
The ‘Genomic insights at other BMI-associated GPCRs’ section reports that GIPR loss-of-function variants are associated with lower BMI and obesity risk in humans, and confirms impaired signaling in cell experiments. It does not report a GIPR genetic preclinical model or show that GIPR antagonism promotes weight loss or prevents weight gain; the mouse weight-gain experiment concerns Gpr75, not Gipr (Gpr75 deletion section; page not provided). (LLM, conf=0.88)
- Partly supportedcites [40] Zhang, Q. et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab. 33, 833–844 (2021). sourceExperimental — accuracy not yet measured
The Results sections on CNS-specific Gipr deletion report lower body weight and reduced weight gain in high-fat-diet-fed mice, supporting prevention of diet-induced weight gain. They do not show that deleting GIPR after obesity develops promotes weight loss; the Discussion says that effect remains to be assessed. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Strong genetic evidence such as GWAS has identified single-nucleotide polymorphisms in Japanese, European and North American populations showing that lower expression or function of GIPR is associated with lower BMI27,29,38”
§ A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings > Discussion
What the sources say
- Could not verifycites [27] Berndt, S. I. et al. Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat. Genet. 45, 501–512 (2013). sourceExperimental — accuracy not yet measured
The Results (BMI-Related Traits) report SNP associations with BMI, and the Abstract describes a study of European individuals. Neither passage links GIPR expression or function to lower BMI or reports the claimed findings across Japanese, European and North American populations. A search for GIPR found it only in a reference about glucose and insulin responses, not in a passage supporting the claim. (LLM, conf=0.75)
- Partly supportedcites [29] Speliotes, E. K. et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat. Genet. 42, 937–948 (2010). sourceExperimental — accuracy not yet measured
The Results (Potential functional roles and pathways analyses; page unavailable) report a BMI-associated variant near GIPR, supporting the GWAS association. They do not establish that lower GIPR expression or function is associated with lower BMI. The copy describes participants of European ancestry, not evidence spanning Japanese, European, and North American populations. (LLM, conf=0.87)
- Partly supportedcites [38] Okada, Y. et al. Common variants at CDKAL1 and KLF9 are associated with body mass index in east Asian populations. Nat. Genet. 44, 302–306 (2012). sourceExperimental — accuracy not yet measured
The paper reports a genome-wide significant association between the GIPR locus and BMI in Japanese subjects and identifies the BMI-decreasing A allele of rs11671664 (main text, labeled Abstract in our copy; page unavailable). It also says the locus had previously been associated with BMI in Europeans. It does not show that the allele lowers GIPR expression or function, or report a finding in North American populations. (LLM, conf=0.88)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The endogenous ligand GIP results in full agonism of the mouse GIPR, and the AMG 133 murine surrogate fully antagonized native GIP (IC50 = 4.1 nM) (Extended Data Fig. 2c).”
§ A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings > Results > AMG 133 structure and in vitro potency
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
71 more claims
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 34
- It may state two separate claims as one. 53
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A monthly subcutaneous injection combining GIP receptor antagonism with GLP-1 RA, and seems to protect against diet-induced obesity as evidenced by models lacking GIP receptor activity.52”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [52]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Maridebart cafraglutide is an antagonistic GIP receptor antibody coupled with a GLP-1 receptor agonist.153”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [153]
The cited source says what the claim attributes to it.
In the citing paper
“In a phase 1, randomized, double-blind placebo-controlled trial in individuals with obesity (without diabetes), this drug resulted in weight loss of 15% over 12 weeks at its highest dose of 420 mg (Table 2).52”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [52]
In the citing paper
“Maritide, the GIPR antagonist/GLP-1RA, resulted in ∼16% body weight loss that was maintained up to a 70% level (hence just 30% of lost weight regained) for 5 months after just 3 monthly doses (128)”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [128]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings > Methods > Phase 1 clinical study
“This paper reports final analysis data from the five SAD and three MAD cohorts (75 participants total) with a date of January 2023.”
§ A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings > Results > AMG 133 clinical study
“A total of 49 participants were enroled into seven SAD cohorts, randomized to receive AMG 133 ranging from 21 to 840 mg (n = 37) or placebo (n = 12) and followed for up to 150 d.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings > Results > AMG 133 clinical study
“A total of 49 participants were enroled into seven SAD cohorts, randomized to receive AMG 133 ranging from 21 to 840 mg (n = 37) or placebo (n = 12) and followed for up to 150 d.”
§ A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings > Methods > Phase 1 clinical study
“The SAD evaluated AMG 133 doses ranging from 21 mg to 840 mg in six cohorts.”
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
Genetics of Food Intake Self-Regulation in Childhood: Literature Review and Research Opportunities
Faith, M. S., Carnell, S., & Kral, T. V. E. (2013) · Human Heredity · doi:10.1159/000353879 · Cited by 7,601
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“The safety profile of AMG 133 was similar to that of GLP-1RAs, including unimolecular GLP-1/GIPR agonist peptides 6,7 .”
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“Unimolecular multi-specific agonist peptides targeting multiple incretin pathways have emerged as promising therapeutic strategies for weight loss 7,8,18–26 .”
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index
MAGIC, Speliotes, E. K., on behalf of Procardis Consortium, Willer, C. J., Berndt, S. I., Monda, K. L., Thorleifsson, G., Jackson, A. U., Allen, H. L., Lindgren, C. M., et al. (2010) · Nature Genetics · doi:10.1038/ng.686 · Cited by 2,912 · cited 1×
“…polymorphisms in Japanese, European and North American populations showing that lower expression or function of GIPR is associated with lower BMI 27,29,38 and genetic preclinical models 30,31,39,40 support the role of GIPR antagonism as a method to promote weight loss and prevent weight gain.”
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“In addition to the incretin effects, GLP-1 promotes satiety 11 and GIP promotes lipid storage and metabolic regulation 12–15 .”
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669 · cited 1×
“In a recent clinical study, individuals with heart failure and preserved ejection fraction who received weekly semaglutide injections (2.4 mg) for 52 weeks experienced substantially improved symptoms and physical function compared to the placebo group 9 .”
InfluentialRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“…polymorphisms in Japanese, European and North American populations showing that lower expression or function of GIPR is associated with lower BMI 27,29,38 and genetic preclinical models 30,31,39,40 support the role of GIPR antagonism as a method to promote weight loss and prevent weight gain.”
Cited by
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Diabetes mellitus—Progress and opportunities in the evolving epidemic
Abel, E. D., Gloyn, A. L., Evans-Molina, C., Joseph, J. J., Misra, S., Pajvani, U. B., Simcox, J., Susztak, K., & Drucker, D. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.029 · Cited by 292
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
GPCR drug discovery: new agents, targets and indications
Lorente, J. S., Sokolov, A. V., Ferguson, G., Schiöth, H. B., Hauser, A. S., & Gloriam, D. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01139-y · Cited by 251
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“Intriguingly, in the small phase I trial of MariTide, some subjects maintained >10% weight loss even 5 months after the last dose of medicine 79 .”
Metadata
- Authors
- Véniant, M. M., Lu, S.-C., Atangan, L., Komorowski, R., Stanislaus, S., Cheng, Y., Wu, B., Falsey, J. R., Hager, T., Thomas, V. A., Ambhaikar, M., Sharpsten, L., Zhu, Y., Kurra, V., Jeswani, R., Oberoi, R. K., Parnes, J. R., Honarpour, N., Neutel, J., & Strande, J. L.
- Affiliations
- Amgen (United States) (US)
- Orange County Research Center (US)
- Corresponding author
- Véniant, Murielle M.
- ORCID
- Venue
- Nature Metabolism
- Published
- 2024-02-05
- Volume
- 6
- Issue
- 2
- Pages
- 290-303
- ISSN
- 2522-5812 (ISSN-L)
- PMC
- PMC10896721
- OpenAlex
- W4391533080
- Semantic Scholar
- 649474b7fd24a627216b72792dc51fcc3798a6a0
- Cited by
- 218
- References
- 42
- Citations by year
- 2026: 72 · 2025: 91 · 2024: 55
- FWCI
- 61.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Metabolism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GIP receptor antagonist, GLP-1 receptor agonists, incretins, obesity, weight loss, metabolic parameters, safety and tolerability, Macaca fascicularis, obese mice
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Humans, Male, Obesity, Peptides, Weight Loss, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. https://app.cochat.ai/papers/10.1038/s42255-023-00966-w
- The paper
- Véniant, M. M., Lu, S.-C., Atangan, L., Komorowski, R., Stanislaus, S., Cheng, Y., Wu, B., Falsey, J. R., Hager, T., Thomas, V. A., Ambhaikar, M., Sharpsten, L., Zhu, Y., Kurra, V., Jeswani, R., Oberoi, R. K., Parnes, J. R., Honarpour, N., Neutel, J., & Strande, J. L. (2024). A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nature Metabolism. https://doi.org/10.1038/s42255-023-00966-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.